{"doi":"10.1089/end.2024.0849","title":"Evaluating Long-Term Oncologic Outcomes of Radiofrequency Ablation for T1a Renal Cell Carcinoma with Minimum 10 Years of Follow-Up","abstract":"<jats:sec>\n                    <jats:title>Introduction:</jats:title>\n                    <jats:p>We aimed to assess long-term outcomes of radiofrequency ablation (RFA) for biopsy-proven renal cell carcinoma (RCC), with a minimum follow-up of 10 years.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:</jats:title>\n                    <jats:p>We retrospectively identified patients who underwent RFA for renal masses at our center between 2004 and 2014. All patients who underwent RFA for a single, unilateral renal mass measuring ≤4 cm and had a minimum follow-up of 10 years were included. Our primary outcome was RCC recurrence. Kaplan–Meier curves were used to identify recurrence-free, metastasis-free, cancer-specific, and overall survival rates. Multivariate binary logistic regression was used to determine predictors of recurrence.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:</jats:title>\n                    <jats:p>A total of 75 patients were included in our study. Median follow-up was 131 months (interquartile range [IQR], 109–151 months). Median tumor size was 2.7 cm (IQR, 2.1–3.3 cm), and the median RENAL nephrometry score was 7 (IQR, 5–8). A total of 70.7% of pathology results showed clear cell RCC. Nine patients experienced RCC recurrence with a median time to recurrence of 54.4 months (IQR, 17.3–70.3 months). Two patients died due to metastatic RCC, and median time to death was 97.5 months (IQR, 55.8–128 months). Overall recurrence-free survival was 88%, and cancer-specific survival was 97%. No patients developed recurrence after 10 years. Univariate and multivariate regression did not identify any predictors of recurrence.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:</jats:title>\n                    <jats:p>RFA is a safe and effective treatment option for T1a RCC. Rates of recurrence and cancer-specific mortality are low at 10 years postprocedure. No patient or tumor factors were identified as predictors for RCC recurrence.</jats:p>\n                  </jats:sec>","journal":"Journal of Endourology","year":2025,"id":655161,"datarank":0.20794415416798362,"base_score":1.3862943611198906,"endowment":1.3862943611198906,"self_citation_contribution":0.20794415416798362,"citation_network_contribution":0.0,"self_endowment_contribution":0.20794415416798362,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":3,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1710107,"name":"Michael Uy","orcid":"0000-0001-9426-7360","position":1,"is_corresponding":false},{"id":339324,"name":"Alan Cheng","orcid":"0000-0002-8213-9115","position":2,"is_corresponding":false},{"id":1710108,"name":"Lamisa Syed","orcid":null,"position":3,"is_corresponding":false},{"id":1710109,"name":"Muaiqel Almuaiqel","orcid":null,"position":4,"is_corresponding":false},{"id":1710110,"name":"Edward Matsumoto","orcid":null,"position":5,"is_corresponding":false},{"id":560134,"name":"Anil Kapoor","orcid":"0000-0001-9180-8029","position":6,"is_corresponding":false},{"id":1491677,"name":"Rahul Bansal","orcid":null,"position":7,"is_corresponding":false},{"id":1488842,"name":"John Kim","orcid":"0000-0002-3037-4308","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Evaluating Long-Term Oncologic Outcomes of Radiofrequency Ablation for T1a Renal Cell Carcinoma with Minimum 10 Years of Follow-Up","abstract":"<jats:sec>\n                    <jats:title>Introduction:</jats:title>\n                    <jats:p>We aimed to assess long-term outcomes of radiofrequency ablation (RFA) for biopsy-proven renal cell carcinoma (RCC), with a minimum follow-up of 10 years.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:</jats:title>\n                    <jats:p>We retrospectively identified patients who underwent RFA for renal masses at our center between 2004 and 2014. All patients who underwent RFA for a single, unilateral renal mass measuring ≤4 cm and had a minimum follow-up of 10 years were included. Our primary outcome was RCC recurrence. Kaplan–Meier curves were used to identify recurrence-free, metastasis-free, cancer-specific, and overall survival rates. Multivariate binary logistic regression was used to determine predictors of recurrence.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:</jats:title>\n                    <jats:p>A total of 75 patients were included in our study. Median follow-up was 131 months (interquartile range [IQR], 109–151 months). Median tumor size was 2.7 cm (IQR, 2.1–3.3 cm), and the median RENAL nephrometry score was 7 (IQR, 5–8). A total of 70.7% of pathology results showed clear cell RCC. Nine patients experienced RCC recurrence with a median time to recurrence of 54.4 months (IQR, 17.3–70.3 months). Two patients died due to metastatic RCC, and median time to death was 97.5 months (IQR, 55.8–128 months). Overall recurrence-free survival was 88%, and cancer-specific survival was 97%. No patients developed recurrence after 10 years. Univariate and multivariate regression did not identify any predictors of recurrence.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:</jats:title>\n                    <jats:p>RFA is a safe and effective treatment option for T1a RCC. Rates of recurrence and cancer-specific mortality are low at 10 years postprocedure. No patient or tumor factors were identified as predictors for RCC recurrence.</jats:p>\n                  </jats:sec>","is_dataset_classified":null,"base_score":1.0986122886681096,"endowment":1.0986122886681096,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"40274368","pmcid":null,"openalex_id":"https://openalex.org/W4409743034","authors":[],"funders":[],"total_grants":0,"fwci":1.497,"citation_percentile":0.80780764,"influential_citations":0,"citation_trend":[{"year":2026,"count":2}],"oa_status":"closed","license":"https://journals.sagepub.com/page/policies/text-and-data-mining-license","oa_locations":[{"url":"https://journals.sagepub.com/doi/full-xml/10.1089/end.2024.0849","host_type":"publisher"},{"url":"https://journals.sagepub.com/doi/pdf/10.1089/end.2024.0849","host_type":"publisher"},{"url":"https://doi.org/10.1089/end.2024.0849","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/40274368","host_type":"repository"}],"fields_of_study":["Renal cell carcinoma treatment","Renal and related cancers","MRI in cancer diagnosis","Humans","Carcinoma, Renal Cell","Kidney Neoplasms","Radiofrequency Ablation","Male","Female","Follow-Up Studies","Treatment Outcome","Middle Aged","Aged","Neoplasm Recurrence, Local","Neoplasm Staging","Time Factors","Kaplan-Meier Estimate","Retrospective Studies","Multivariate Analysis","Disease-Free Survival"],"mesh_terms":["Radiofrequency Ablation","Aged","Carcinoma, Renal Cell","Female","Follow-Up Studies","Humans","Kidney Neoplasms","Male","Middle Aged","Neoplasm Recurrence, Local","Neoplasm Staging","Retrospective Studies","Time Factors","Multivariate Analysis","Treatment Outcome","Disease-Free Survival","Kaplan-Meier Estimate"],"keywords":["Medicine","Renal cell carcinoma","Radiofrequency ablation","Term (time)","Ablation","Kidney cancer","Nephrology","Urology","Surgery","General surgery","Oncology","Internal medicine","small renal mass"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-11T09:53:51.613971Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}